Checkpoint Therapeutics (Checkpoint Therapeutics) Total Stockholders Equity : $-10.25 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Total Stockholders Equity?

Checkpoint Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-10.25 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Checkpoint Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.29. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Checkpoint Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Checkpoint Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Checkpoint Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Total Stockholders Equity Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

18.85

35.38

29.75

-19.48

-13.05

Checkpoint Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															-22.18	-23.27	-19.04	-13.05	-10.25

Checkpoint Therapeutics (NAS:CKPT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Checkpoint Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-10.25	-	0)	/	35.6863
	=	-0.29

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Checkpoint Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-10.25
	=	0.00

Checkpoint Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CZTA:Germany CZTA:Germany

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Executives

William Garrett Gray	officer: See Remarks	2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii	director, officer: CEO, President and Director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon	director	C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman	director	464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen	director	2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020